Applicant: Salvatore Albani Serial No.: 09/828,574

Filed: April 6, 2001

Page 2 of 12

PATENT ATTORNEY DOCKET NO.: UCSD1310-1


## **AMENDMENTS**

Please enter the following rewritten claims:

- 5. (Amended) The substantially pure peptide of claim 1, wherein the peptide is at least 70% identical to a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.
- 6. (Amended) The substantially pure peptide of claim 5, wherein the peptide is at least 80% of identical to a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.
- 7. (Amended) The substantially pure peptide of claim 5, wherein the peptide is at least  $90^{\circ}$  of identical to a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.
- 8. (Amended) The substantially pure peptide of claim 5, wherein the peptide is at least  $95^{\circ}_{0}$  identical to a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.
- 9. (Amended) The substantially pure peptide of claim 5, wherein the peptide has a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.
- 21. (Amended) The substantially pure peptide of claim 5, wherein one or more amino acid of the peptides selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10 has been substituted by one or more amino acid having a similar size, charge and/or polarity.
- 34. (Amended) The immunomodulating composition of claim 33, wherein the fragment binds to at least one molecule selected from the group consisting of HLADR1, DR4, and DR7.

Applicant: Salvatore Albani PATENT Serial No.: 09/828,574 ATTORNEY DOCKET NO.: UCSD1310-1

Filed: April 6, 2001 Page 3 of 12



- 43. (Amended) A method for treating or preventing an immune-mediated disease in a subject having or at risk of having the disease comprising administering to the subject, an effective amount of a substantially pure peptide comprising a fragment of a stress protein that binds to MHC class II molecules in a pharmaceutically acceptable carrier, wherein the peptide modulates an immune response, thereby treating or preventing the disease.
- 51. (Amended) The method of claim 34, wherein the substantially pure peptide has a sequence selected from the group consisting of SBQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.
- 53. (Amended) The method of claim 52, wherein the fragment binds to at least one molecule selected from the group consisting of HLADR1, DR4, and DR7.
- 59. (Amended) The method of claim 52, wherein the substantially pure peptide has a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.